{"data":{"type":"company_profile","id":125437,"entity_id":"wefunder:company:125437","attributes":{"canonical_url":"https://wefunder.com/databiologics","generated_at":"2026-06-13T12:35:58Z","updated_at":"2026-06-13T05:01:03Z","entity_ids":{"company":"wefunder:company:125437","slug":"wefunder:company_slug:databiologics"},"profile_visibility":{"owner_published":true,"public_search_results":true,"site_search_listed":true,"privacy_mode":"promote","invite_only":false},"provenance":{"source":"wefunder_public_company_profile","as_of":"2026-06-13T12:35:58Z","claims":{"total_amount_raised":{"source":"FrontCompanySummary#amount_raised","last_verified_at":"2026-06-13T05:01:03Z","as_of":"2026-06-13T12:35:58Z","confidence":"high"},"total_investors":{"source":"FrontCompanySummary#number_of_investors","last_verified_at":"2026-06-13T05:01:03Z","as_of":"2026-06-13T12:35:58Z","confidence":"high"},"active_raise_states":{"source":"Fundraise.visible(nil, nil)","last_verified_at":"2025-02-06T01:17:55Z","as_of":"2026-06-13T12:35:58Z","confidence":"high"},"latest_fundraise_state":{"source":"Fundraise.visible(nil, nil).order(funding_started_at)","last_verified_at":"2025-02-06T01:17:55Z","as_of":"2026-06-13T12:35:58Z","confidence":"medium"}}},"company":{"id":125437,"entity_id":"wefunder:company:125437","slug":"databiologics","name":"DataBiologics","tagline":"Harnessing real patient feedback to benchmark providers and products in cash-pay medicine.","story":"IntroductionDataBiologics is transforming regenerative medicine by providing the essential evidence that physicians and patients need to make informed treatment choices in a field currently lacking robust data. Regenerative medicine, involving treatments like platelet-rich plasma (PRP), shockwave therapy, and stem cells derived from patient fat or bone marrow, is an exciting but largely unregulated frontier. The lack of predictable outcomes and clinical evidence often makes it seem like the \"Wild West.\"Platform OverviewDataBiologics fills this gap with an automated software platform that enables private practitioners to collect, analyze, and share real-world evidence effectively. Unlike costly and complex research systems used in academic hospitals, DataBiologics' solution is designed for everyday clinics, empowering practitioners to validate the effectiveness of new therapies. This allows physicians to offer better care while also supporting patients in confidently investing in treatments not typically covered by insurance.Company TractionDataBiologics has experienced remarkable traction, now serving over 200 providers across the US and Canada, fueled entirely by organic growth and the influence of respected thought leaders in regenerative medicine. Our early adopters, many of whom are prominent figures in their specialties, have become our biggest advocates, sharing their success stories and driving interest within the physician community. This network effect has allowed us to grow rapidly without traditional marketing efforts, proving the effectiveness and value of our platform through real-world results and peer endorsements. The strong support from influential clinicians underscores our credibility and solidifies our leadership in the regenerative medicine space.Growing Patient DemandThe growing demand for regenerative medicine is driven in large part by an aging population that is increasingly prioritizing health, mobility, and quality of life. Traditional treatments often fall short of addressing chronic conditions like osteoarthritis or sexual dysfunction without significant side effects or invasive procedures.Patients today are seeking more personalized, natural, and less invasive healthcare solutions, and they are willing to invest directly in their wellbeing. This trend is evident in the rise of medical tourism, with individuals traveling abroad for treatments that may not yet be widely available or approved in their home countries. Cash-pay options like PRP and stem cell therapies offer exactly what many of these patients are looking for: a way to improve their health outcomes without the limitations imposed by insurance companies or down-time associated with more invasive standard of care.This willingness to pay out-of-pocket reflects a broader shift towards consumer-driven healthcare, where patients are seeking control, value, and evidence that their investments in their health will truly pay off.Physician Adoption of Regenerative MedicineThe healthcare landscape is changing, with a growing number of patients seeking natural, less invasive options for managing age-related conditions like osteoarthritis and chronic pain. Cash-pay treatments such as PRP and shockwave therapy provide an attractive solution, offering immediate revenue without the complexity of insurance or the pressures of declining reimbursement.A simple weekend training course allows any licensed provider—from nurse practitioners to surgeons—to learn the procedure, which involves using a centrifuge and specialized kits to process and inject blood. The low cost and seamless integration into existing clinic setups make it an easy new service line for practices looking to meet patient demand.Field Challenges - Misinformation and Lack of EvidenceRegenerative medicine is often compared to the \"Wild West,\" and for good reason. Despite the exciting potential of biologic treatments like PRP, there is a disturbing lack of standardized evidence to support their use.\u0026nbsp;Patients face a landscape full of flashy marketing claims, but without the clinical data to validate them, these treatments can feel like a gamble. Adding to the confusion is the sheer number of available devices, most of which have only achieved the minimum FDA approval necessary to be marketed. This inconsistency in device quality, processing methods, and practitioner expertise makes it incredibly difficult for patients to make informed decisions.The cost disparities are also striking. Depending on the biologic used, patients can pay anywhere from $1500 for a single PRP injection to over $40k for a series of stem cell treatments. Without adequate, accessible evidence to show what actually works and why, these price tags can feel like little more than a gamble. Patients are effectively placing their trust in a treatment and provider without any assurance that it is backed by reliable clinical proof.\u0026nbsp;DataBiologics Solution and BenefitsDataBiologics is bringing order and clarity to regenerative medicine with a standardized software platform that collects, analyzes, and shares real-world evidence on treatments like PRP and other emerging technologies.\u0026nbsp;Our platform allows physicians to gather long-term patient outcome data in real time using an easy-to-use automated system, which helps them understand what works best for different patient profiles. By aggregating data across a network of clinics, DataBiologics provides a valuable tool for benchmarking, improving practice performance, and building patient trust.Customer Growth and Platform UtilizationDataBiologics has gained incredible momentum by addressing a significant gap in regenerative medicine: the lack of trustworthy, evidence-backed outcomes data that empowers both physicians and patients. Since our launch, we have rapidly expanded our clinician network and accumulated unique patient data that is unavailable anywhere else in cash-pay regenerative medicine.\u0026nbsp;Our growth is evident in our rapid recurring revenue growth, fueled largely by early adopters who have driven word-of-mouth referrals. This surge in adoption has led to over 26,000 active patient cases, more than doubling enrollments in just 12 months.Early Adopter LoyaltyEarly adopters have not only been crucial in spreading awareness but have also demonstrated impressive loyalty, with 82% of early trial users converting to paying customers. This high conversion rate reflects the strong value they derive from our platform in terms of improving patient engagement, gathering evidence for better outcomes, and ultimately growing their practices.\u0026nbsp;Furthermore, our paying customer retention rate stands at an impressive 92%, indicating that once clinicians integrate our platform, they see ongoing, sustainable benefits. This high retention is due to our consistent focus on providing user-driven features and insights that meet the everyday needs of busy healthcare providers.\u0026nbsp;Together, the combination of rapid network expansion, strong conversion rates, and enduring loyalty demonstrates the measurable impact and value that DataBiologics delivers to the regenerative medicine community.Academic Validation of an Emerging FieldDataBiologics has been at the forefront of regenerative medicine, staying ahead of the curve in an evolving field where adoption is rapidly accelerating. In the past four years, the field has gained credibility, with institutions like Mayo Clinic, Stanford, and Cleveland Clinic now formally recognizing its potential. While these academic leaders are just beginning to establish the necessary groundwork for mainstream adoption, DataBiologics is already leading with a wealth of real-world data unmatched in scope and scale.Our Network is Ahead of the CurveOur platform now manages over 20,000 active patient cases, collected by a growing nationwide network of clinicians. Unlike traditional, slow-moving research models limited to isolated trials, DataBiologics provides a real-time, comprehensive dataset that empowers clinical decision-making today. This evidence base not only guides our users but also sets a benchmark for institutions, helping them advance the field more efficiently.What sets DataBiologics apart is our ability to benchmark and rank physicians and products across diverse, unaffiliated practices—something nearly impossible in siloed, insurance-based healthcare.\u0026nbsp;Practitioners can compare their outcomes to national standards, identify leaders, and refine their methods based on peer insights. We are lightyears ahead in creating a standardized, transparent, and data-driven foundation for regenerative medicine, far surpassing what traditional systems can achieve.Leading the Future with AIDataBiologics is uniquely positioned to drive the future of regenerative medicine by harnessing AI through our expansive, clean, and standardized database. Our AI-powered roadmap streamlines and accelerates patient access to treatments that enhance healthspan—not just lifespan.Humans in the Loop for Reliable InsightsOur strength lies in meticulously standardized real-world data combined with experienced experts—our \"humans in the loop\"—who provide essential context. This blend makes DataBiologics the most reliable and actionable resource in regenerative medicine, ensuring insights are grounded in both clinical realities and advanced data science.Transforming Data InteractionsOur platform revolutionizes how physicians and patients interact with data. Using our fundamental database, our AI ecosystem powers diverse use cases, from medical education and compliance-focused marketing to advanced patient-provider matching. Our tools can generate patient education materials, medical education content, and peer-reviewed publications—all while adhering to FCC/FDA compliance, delivering tailored insights to every stakeholder.Empowering Patients and ProvidersWe can use the power of AI to benchmark outcomes, rank providers, and create digital twin profiles, offering unprecedented insights to patients and clinicians alike. Patients can find the best-fit providers based on real-world data, while physicians gain access to best practices by learning from aggregated data across different clinics.Democratizing Access to KnowledgeBy democratizing access to vital data, DataBiologics makes it easier for patients to find the best options for their needs, and for providers to refine care continuously. Our holistic, AI-driven approach reduces costs, enhances efficiency, and expands access to high-quality regenerative treatments, paving the way for the future of medicine.Founded by Physicians for PhysiciansDataBiologics was founded to address a critical gap in regenerative medicine—a lack of credible, standardized data. The idea originated with our physician founders, who saw firsthand how the absence of reliable outcomes data was limiting the adoption and growth of regenerative treatments. Recognizing the need for a solution that could empower both clinicians and patients, they envisioned a platform that would collect, validate, and share real-world evidence in a streamlined way.Leah Braddell: Visionary LeadershipLeah Braddell, CEO and Chief Technology Officer, brings over two decades of experience in healthcare, combining expertise in commercial leadership, biomedical engineering, and data science. Known for her unique experience and award-winning success with disruptive technologies like Intuitive's da Vinci surgical robotics system, Leah joined DataBiologics in late 2022. Her career spans roles in sales, marketing, custom analytics, and clinical adoption of new medical technologies. Leah is driven by a central question: why isn’t healthcare adopting evidence-driven innovation faster? Her solution is a platform that’s simple enough for any private practice to use but powerful enough to drive industry-wide change.Luke Malanga: Driving Product VisionLuke Malanga, COO and Chief Product Officer, is a tech-savvy entrepreneur and the son of the late co-founder\u0026nbsp;Dr. Gerard Malanga MD, a renowned educator in the field. Luke complements Leah's deep expertise with his passion for using data to solve complex problems. His forward-thinking approach has been pivotal in developing DataBiologics’ product roadmap, ensuring each feature meets the needs of end users—physicians and patients. Luke's focus on user experience, scalability, and seamless AI integration has transformed the company’s vision into a functional and impactful platform.Brent Weber: Scaling InnovationBrent Weber is a seasoned entrepreneur, technologist, and innovation leader who has founded and scaled two tech startups, bringing deep expertise in product strategy, development, and lean innovation. As a Principal at Moves the Needle, he led programs for Fortune 500 companies, helping them drive growth through lean startup methodologies and data-driven decision-making. With a global career spanning consulting, coaching hundreds of product teams, and speaking at innovation conferences worldwide, Brent combines technical excellence and seasoned engineering management with strategic vision to create impactful, scalable solutions.The Ecosystem of ExpertiseDataBiologics' growth and expansion are driven not just by its founders, but by an ecosystem of \"humans in the loop\"—a community of leading practitioners, data scientists, engineers, and regulatory experts. This collective expertise ensures that every aspect of data collection, algorithm development, and insight generation is contextualized, relevant, and actionable. The blend of human expertise and cutting-edge technology positions DataBiologics at the forefront of regenerative medicine, pushing the boundaries of what’s possible in healthcare.Organic Growth through Physician InfluencersDataBiologics has grown organically, driven primarily by word-of-mouth within the physician community. Adoption of innovative solutions like regenerative medicine is often led by influential peers—doctors who use the platform, see the results, and share their successes.\u0026nbsp;Our early adopters, who recognized the potential of regenerative treatments but were frustrated by the lack of credible evidence, have become our strongest advocates. Their success stories have formed the foundation of our growth, enabling us to expand rapidly without heavy marketing investments.Expansion of Services to Industry and ResearchersThe commitment of these early adopters has not only expanded our clinician network but also attracted interest from medical device companies and other research groups seeking to collaborate.\u0026nbsp;These industry partners are eager to tap into the high volume of real-world patient feedback we’ve collected across numerous products and treatments. By leveraging the unique insights generated by our platform, medical device manufacturers can understand product efficacy in real-world settings, refine their devices, and foster collaboration with our physician network.\u0026nbsp;Likewise, research groups are utilizing our data to accelerate studies, making DataBiologics a central hub for innovation and validation in the field. This expansion underscores the value of our comprehensive dataset and positions us as a key player in advancing regenerative medicine through cross-industry collaboration.Platform Evolution - IMPACT and ACCESSThe evolution of DataBiologics has led to the development of two distinct products. Our IMPACT platform serves healthcare providers by tracking and analyzing practice data, contributing to our growing IMPACT registry database.\u0026nbsp;The ACCESS platform offers HIPAA-compliant, anonymized data insights to medical device companies and researchers. Through our IMPACT and ACCESS products, we've created a new dynamic between device manufacturers and providers, facilitating collaboration and shared learning. Medical device companies can now gain real-world insights and connect directly with leading practitioners, creating a virtuous cycle of innovation, feedback, and product improvement.Subscription ModelDataBiologics offers multi-tiered subscription models tailored to the diverse needs of healthcare providers and industry partners. The IMPACT plan includes Starter, Essentials, and Performance tiers ranging from $249 to $4,495 per year, offering scalability in data collection, patient management, and analytics.\u0026nbsp;The ACCESS plan provides Basic, Standard, and Premium options, starting at $4,500 per year, providing data extracts, advanced analytics, professional services, and collaborative solutions. This approach ensures each user, whether a clinic or a medical device company, can choose the right level of engagement, enabling scalable growth and impactful collaboration.Regulatory Market Factors Driving UrgencyThe need for capturing Patient Reported Outcomes (PROs) is becoming increasingly urgent, driven by significant regulatory and market shifts.\u0026nbsp;TEFCA\u0026nbsp;regulations now enforce interoperability and seamless data sharing, pushing healthcare systems to make patient data more accessible for clinical decision-making.\u0026nbsp;CMS\u0026nbsp;is also introducing\u0026nbsp;PRO requirements\u0026nbsp;that will directly impact reimbursement structures, with clinicians in orthopedics required to report patient-reported outcomes to secure optimal payments by 2027.\u0026nbsp;Additionally, the\u0026nbsp;European Medicines Agency (EMA)\u0026nbsp;mandates that manufacturers track real-world outcomes for\u0026nbsp;regulatory compliance, emphasizing the need for robust data collection to support market access.DataBiologics Positioned for Enabling Compliance and Care ImprovementThese evolving requirements are creating demand for comprehensive, standardized data that both providers and manufacturers can effectively leverage. DataBiologics is uniquely positioned to meet this need, with our platform already focused on collecting and analyzing real-world outcomes data. As regulatory frameworks increasingly emphasize patient-reported metrics, the value of our comprehensive database continues to grow, allowing providers to stay compliant while improving patient care and demonstrating the effectiveness of their treatments.Driving Future Demand and Market LeadershipThe regulatory push for outcomes tracking not only positions DataBiologics as an immediate compliance solution but also accelerates future demand for our platform. Our commitment to real-world data collection, paired with a strong network of clinician users, places us as a pivotal player in an emerging and disruptive market.\u0026nbsp;As stakeholders across the healthcare ecosystem—including providers, medical device companies, and regulators—recognize the necessity of high-quality, accessible patient data, DataBiologics is poised to lead this shift. By providing the infrastructure necessary to meet both current and evolving regulatory requirements, we are not merely keeping up with industry changes—we are shaping the future of a more transparent, data-driven approach to regenerative medicine.Market SizeThe market opportunity for DataBiologics is immense, and our go-to-market strategy is precisely crafted to capture the expanding demand in the regenerative medicine landscape.\u0026nbsp;Our Total Addressable Market (TAM) is approximately $125 billion, encompassing the U.S. healthcare research and marketing spend, driven by an increasing interest in cash-based treatment options like regenerative therapies.\u0026nbsp;From this broad market, we've identified our Serviceable Available Market (SAM) at $4.7 billion, which includes over 1 million healthcare providers who have the potential to integrate regenerative or other innovative and cash-based treatments into their practices.\u0026nbsp;Within this framework, our Serviceable Obtainable Market (SOM) represents a $2.9 billion opportunity focused on 650,000 ideal clinicians.\u0026nbsp;These ideal profile clinicians, operating across specialties like physical medicine and rehabilitation, sports medicine, pain management, orthopedic surgery, chiropractic/physical therapy, urology, and gynecology, are most likely already adopting regenerative and cash-based options or can be enabled to do so with low barrier to entry.\u0026nbsp;These providers are perfectly positioned to benefit from the evidence-backed insights our platform and physician network provides.\u0026nbsp;Targeted Go-to-Market StrategyTo accelerate our market penetration, we are implementing a high-powered Customer Relationship Management (CRM) system that is integral to our go-to-market strategy. Our CRM approach involves curated outbound mailing lists, strategic social media marketing, SEO optimization, and messaging tailored specifically to clinicians whose practice profiles match those of our current successful users.By utilizing advanced segmentation and targeting techniques, our CRM groups practitioners with similar characteristics, challenges, and potential as our existing customers, ensuring a high conversion likelihood.This personalized outreach, coupled with our proven word-of-mouth referrals, will help us expand efficiently and cost-effectively. Our goal is to drive rapid adoption among those who are most likely to see immediate value from our platform, thereby establishing a scalable foundation for deeper market penetration and long-term growth. By focusing on evidence-based, cash-pay solutions, we are not only transforming patient care but also helping providers grow their practice capabilities.Scaling Marketing and Sales through FundingOur ongoing fundraising efforts will further bolster our go-to-market strategy by supporting automation and scaling of our outbound marketing efforts. These funds will help us target potential IMPACT subscribers while expanding direct sales and support for our high-value ACCESS product. We also plan to enhance our presence at medical conferences to expand our brand positioning and relevance in the market.Additionally, investments in our AI-powered product roadmap will accelerate development and support international expansion. While we expect to achieve profitability by early next year, we intend to pursue follow-on funding in a priced round to expedite growth and enhance our market position, ultimately setting up the company for a successful exit for our early shareholders. With this strategy, DataBiologics is positioned to lead in an emerging and disruptive market, creating value across the healthcare ecosystem.Path to a Valuable ExitDataBiologics is uniquely positioned for success, with a clear path to a highly valuable exit that aligns with precedents in healthcare data and patient experience. Comparable exits such as\u0026nbsp;Flatiron Health, acquisition by Roche for $1.9 billion and\u0026nbsp;Press Ganey's\u0026nbsp;$4.2 billion sale to LGP and Ares Management highlight the high value of data-driven healthcare solutions.\u0026nbsp;DataBiologics is creating a similar niche by aggregating and standardizing real-world treatment data, providing evidence-based insights that drive healthcare quality and decision-making. With an expanding clinician network and partnerships with industry leaders, we are positioned as an attractive acquisition target for healthcare giants, tech companies, or private equity firms aiming to transform healthcare delivery.The Opportunity to Transform HealthcareDataBiologics stands at the forefront of an emerging healthcare revolution, uniquely positioned to transform the future of regenerative medicine. With strong early traction, including a rapidly expanding clinician network, high conversion and retention rates, and significant ARR growth, we have proven the value and demand for our evidence-based platform.\u0026nbsp;By establishing a firm foothold in a niche, high-growth field, we offer a distinct first-mover advantage in an industry ripe for disruption. Our strengths lie in our comprehensive, real-world data collection, AI-driven insights, and our ability to democratize access to high-quality treatments that extend and enhance healthspan.\u0026nbsp;We invite investors to take an active role in this journey, contributing to the transformation of healthcare and helping us expand our impact globally. Join us in unlocking the full potential of regenerative medicine and shaping a more transparent, effective, and patient-centric future.","location":"Mesa, AZ","website":"https://www.databiologics.com/","total_amount_raised":159338,"total_investors":60,"is_funded":true,"is_active":true,"quality_score":3,"related_urls":["https://wefunder.com/databiologics","https://www.databiologics.com/"]},"media":{"share_image_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/125437/xxl_blob.jpg","logo_url":"https://uploads.wefunder.com/uploads/company/logo/125437/large_blob.png","header_media_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/125437/standard_blob.jpg","cover_photo_url":"https://uploads.wefunder.com/uploads/company/header_media_photo/125437/standard_blob.jpg"},"links":{"company_url":"https://www.databiologics.com/","linkedin_url":"https://linkedin.com/company/databiologics/","twitter_url":"https://twitter.com/DataBiologics"},"highlights":[{"id":62781,"name":"venture_backed","url":"venturebacked","presentable_name":"VC-Backed","description":"Raised $250K or more from a venture firm","image_url":"https://uploads.wefunder.com/2021/profile-highlights-check.svg"},{"id":75539,"name":"fast_growth","url":"fastgrowth","presentable_name":"Fast Growth","description":"Revenue growing 2X/yr for at least prior 6 months","image_url":"https://uploads.wefunder.com/2021/profile-highlights-bar-graph.svg"}],"quick_facts":[{"index":1,"claim_id":"claim-fact-1","value":"Rapidly growing market, 6X revenue growth Aug 2023-24 and over $500k in ARR."},{"index":2,"claim_id":"claim-fact-2","value":"Large national database of 130+ clinics, 220+ providers, 20k+ patients tracked."},{"index":3,"claim_id":"claim-fact-3","value":"Easy data entry, pre-loaded outcomes assessments, automated patient messaging, data visualization."},{"index":4,"claim_id":"claim-fact-4","value":"Glowing customer reviews and testimonials."},{"index":5,"claim_id":"claim-fact-5","value":"Clients include Emory Healthcare, OhioHealth, SoftWave, and QC Kinetix"},{"index":6,"claim_id":"claim-fact-6","value":"Over 90% retention of paying customers."},{"index":7,"claim_id":"claim-fact-7","value":"Backed by two Venture accelerator/studios."},{"index":8,"claim_id":"claim-fact-8","value":"Founded by physicians, for physicians."}],"team":[{"id":3217930,"entity_id":"wefunder:company_role:3217930","user_entity_id":"wefunder:user:2771055","role":"founder","name":"Leah Braddell","title":"CEO \u0026 CTO","bio":"20+ years broad industry experience, accomplished biomedical R\u0026amp;D engineer turned award winning sales/marketing leader at Intuitive Surgical, deep tech investor, highly experienced real-world health data scientist, technical, and commercial recruiter.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/3217930/square_blob.jpg?1727750778","profile_url":"https://wefunder.com/leah.braddell","linkedin_url":"https://linkedin.com/in/leahbraddell/","related_urls":["https://wefunder.com/leah.braddell"]},{"id":5255670,"entity_id":"wefunder:company_role:5255670","user_entity_id":"wefunder:user:2809693","role":"founder","name":"Luke Malanga","title":"COO \u0026 CPO","bio":"Deep domain knowledge and influential physician networker. Lifelong experience with regenerative medicine physicians and treatment market.","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/5255670/square_blob.jpg?1727755408","profile_url":"https://wefunder.com/luke.malanga","related_urls":["https://wefunder.com/luke.malanga"]},{"id":5099732,"entity_id":"wefunder:company_role:5099732","user_entity_id":"wefunder:user:4430133","role":"founder","name":"Christopher Rogers","title":"Chief Medical Officer","bio":"Founder, San Diego Orthobiologics Medical Group; Medical Director, Personalized Stem Cells, Inc","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/5099732/square_blob.jpg?1727739247","profile_url":"https://wefunder.com/christopher.rogers.1","personal_url":"https://linkedin.com/me?trk=p_mwlite_feed-secondary_nav","linkedin_url":"https://linkedin.com/in/christopher-rogers-m-d-19a0a1a4/","related_urls":["https://wefunder.com/christopher.rogers.1","https://linkedin.com/me?trk=p_mwlite_feed-secondary_nav"]},{"id":5099731,"entity_id":"wefunder:company_role:5099731","role":"founder","name":"Jay Bowen","title":"Chief Science Officer","bio":"President, American Medical Shockwave Society; Medical Director, New Jersey Regenerative Institute, LLC","avatar_url":"https://uploads.wefunder.com/uploads/company_role/custom_photo/5099731/square_blob.jpg?1727739247","linkedin_url":"https://linkedin.com/in/jay-bowen-b294b746/","related_urls":[]}],"featured_investors":[{"id":9931,"entity_id":"wefunder:company_investor_profile:9931","investor_profile_id":3981414,"investor_profile_entity_id":"wefunder:investor_profile:3981414","subject_entity_id":"wefunder:user:4490192","name":"Rowan V Paul","role_title":"","bio":"Physician, MedTech, Advisory, Angel","avatar_url":"https://wefunder.com/rails/active_storage/blobs/redirect/eyJfcmFpbHMiOnsiZGF0YSI6MjEwNzUyLCJwdXIiOiJibG9iX2lkIn19--57d4fc11ea2d4aa9018ecde099b71ab37f62a1a4/filename","profile_url":"https://wefunder.com/rowan.v.paul","endorsement_quote":"I believe in the team, the mission, and the proof is in the pudding for changing my practice in real time. Importantly I am investing as a tribute to Gerry Malanga, R.I.P., and his constant support and mentorship. The company has proven it's ability to grow and has been incredible to work with for almost 5 years. Leah Braddell, the CEO is a gem, Luke Malanga has been incredibly responsive to ideas and Chris Rogers is a legend in our field. I want to do my part to bring the tidewater up in our field, improve our quality and democratize research and development.","endorsement_name":"","investment_total":50000,"investment_info":"Invested $50,000 this round","is_lead_investor":true,"memo_paid_for_by_company":false,"related_urls":["https://wefunder.com/rowan.v.paul"]},{"id":9385,"entity_id":"wefunder:company_investor_profile:9385","investor_profile_id":3632618,"investor_profile_entity_id":"wefunder:investor_profile:3632618","subject_entity_id":"wefunder:notable_investor:2177","name":"EXPERT DOJO","role_title":"","bio":"EEXPERT DOJO IS AN INTERNATIONAL EARLY-STAGE STARTUP ACCELERATOR IN SOUTHERN CALIFORNIA.WE INVEST $50,000 IN EACH OF OUR STARTUPS AND HELP THEM GET TRACTION AND SCALE FASTER THAN THEY COULD EVER DO BY THEMSELVES.","avatar_url":"https://wefunder.com/rails/active_storage/blobs/redirect/eyJfcmFpbHMiOnsiZGF0YSI6MTU3Nzg1LCJwdXIiOiJibG9iX2lkIn19--25c6ef3d2d8c411ee53135ee653e1af925b750a3/filename","profile_url":"https://wefunder.com/expert.dojo.1","endorsement_name":"","is_lead_investor":false,"memo_paid_for_by_company":false,"related_urls":["https://wefunder.com/expert.dojo.1"]},{"id":9791,"entity_id":"wefunder:company_investor_profile:9791","investor_profile_id":3963483,"investor_profile_entity_id":"wefunder:investor_profile:3963483","subject_entity_id":"wefunder:notable_investor:13386","name":"Launch Factory","role_title":"","bio":"Launch Factory is an early-stage venture studio based in San Diego, CA.","avatar_url":"https://uploads.wefunder.com/2021/user_default_icon_circle.png","profile_url":"https://wefunder.com/launch.factory.1","endorsement_name":"","is_lead_investor":false,"memo_paid_for_by_company":false,"related_urls":["https://wefunder.com/launch.factory.1"]}],"investor_memos":[],"tab_counts":{"posts":6,"ask_questions":7,"featured_investors":3,"faq_entries":5},"active_fundraises":[{"id":121202,"entity_id":"wefunder:fundraise:121202","state":"successful","offering_type":"4(a)(6)","funding_type":"note","structure":"ttw","security_type":"","currency":"USD","testing_the_waters":true,"min_purchase":100,"max_purchase":9,"funding_target":1235000.0,"minimum_target":"50000.0","maximum_target":"1235000.0"},{"id":121201,"entity_id":"wefunder:fundraise:121201","state":"successful","offering_type":"4(a)(6)","funding_type":"note","structure":"safe","security_type":"equity","currency":"USD","testing_the_waters":false,"min_purchase":100,"max_purchase":9,"funding_target":50000.0,"minimum_target":"50000.0","maximum_target":"1235000.0","funding_started_at":"2024-09-26T22:04:43Z","funding_closed_at":"2025-05-01T04:01:06Z","auto_close_at":"2025-05-01T03:59:59Z"}],"latest_fundraise":{"id":121202,"entity_id":"wefunder:fundraise:121202","state":"successful","offering_type":"4(a)(6)","structure":"ttw","testing_the_waters":true,"can_invest_now":false,"funding_started_at":null,"funding_closed_at":null,"terms":{"eb":"$9M","nb":"$10M","txt":"valuation cap"}},"recent_posts":[{"id":176930,"entity_id":"wefunder:feed_item:176930","type":"FeedItem::Update","visibility":"public","title":"DataBiologics Registry Powers NYU Study on PRP","preview":"We’re thrilled to share a huge win for the DataBiologics community—a subset of our real-world outcomes data has been independently analyzed by one of the top academic institutions in the country.A team of physicians and statisticians at\u0026nbsp;NYU Langone Health\u0026nbsp;conducted a retrospective analysis of PRP treatment data from our registry, and their findings were recently\u0026nbsp;accepted by the American Academy of Pain Medicine. 🔍 What They Found:Patients with\u0026nbsp;knee osteoarthritis\u0026nbsp;who ...","published_at":"2025-04-22T17:54:52Z","author_name":"Luke Malanga","url":"/feed/176930","canonical_url":"https://wefunder.com/feed/176930"},{"id":181504,"entity_id":"wefunder:feed_item:181504","type":"FeedItem::Update","visibility":"public","title":"FINAL DataBiologics Investment Webinar + Q\u0026amp;A","preview":"Join Us for a Live Webinar \u0026 Q\u0026A!📅\u0026nbsp;Date:\u0026nbsp;Wednesday, April 24th⏰\u0026nbsp;Time:\u0026nbsp;8 PM EST📣\u0026nbsp;Host:\u0026nbsp;Luke Malanga, COO of DataBiologics🎙️\u0026nbsp;Guest:\u0026nbsp;Dr. Rowan Paul, Provider \u0026 Lead InvestorGet an inside look at our current investment opportunity, what’s ahead on our roadmap, and why Dr. Paul chose to invest in the platform he uses every day.Don’t miss this chance to ask your questions and learn how we’re building the future of evidence-based care!Register here:\u0026nbsp;https...","published_at":"2025-04-16T15:07:02Z","author_name":"Luke Malanga","url":"/feed/181504","canonical_url":"https://wefunder.com/feed/181504"},{"id":181348,"entity_id":"wefunder:feed_item:181348","type":"FeedItem::Update","visibility":"public","title":"How DataBiologics Took Center Stage at IOF MAX","preview":"Last month, the\u0026nbsp;IOF MAX Conference\u0026nbsp;brought together the brightest minds in regenerative medicine—and\u0026nbsp;DataBiologics\u0026nbsp;was a major part of the conversation.💬 From\u0026nbsp;podium presentations\u0026nbsp;to\u0026nbsp;panel discussions, our platform was highlighted as the go-to software for tracking\u0026nbsp;real-world outcomes\u0026nbsp;in orthobiologics.📊 Multiple speakers shared data from\u0026nbsp;DataBiologics-powered studies, spotlighting how outcome tracking is helping providers refine treatment pro...","published_at":"2025-04-11T14:19:11Z","author_name":"Luke Malanga","url":"/feed/181348","canonical_url":"https://wefunder.com/feed/181348"},{"id":178438,"entity_id":"wefunder:feed_item:178438","type":"FeedItem::Update","visibility":"public","title":"DataBiologics Selected as Awardee of 2024 Arizona Innovation Challenge","preview":"Earlier this month, DataBiologics was selected as an awardee in the 2024 Arizona Innovation Challenge! This prestigious recognition celebrates the best in entrepreneurial endeavors throughout the state of Arizona. We're proud to stand alongside Arizona's most innovative companies.\u0026nbsp;“We’re incredibly proud to celebrate this year’s Arizona Innovation Challenge awardees,” said Sandra Watson, President and CEO of the Arizona Commerce Authority. “This year’s awardees represent the extensive ta...","published_at":"2024-12-26T21:08:56Z","author_name":"Luke Malanga","url":"/feed/178438","canonical_url":"https://wefunder.com/feed/178438"},{"id":177172,"entity_id":"wefunder:feed_item:177172","type":"FeedItem::Update","visibility":"public","title":"DataBiologics Investment Webinar + Q\u0026amp;A","preview":"Join Us for a Live Webinar \u0026 Q\u0026A! 📅 Date: Monday, Nov 4th ⏰ Time: 8 PM EST 📣 Host: Leah Braddell, CEO of DataBiologics Learn about our vision, growth, and why now is the perfect time to invest in our Wefunder campaign. Don’t miss this chance to ask your questions and hear how we’re transforming healthcare with real-world data!Register here: https://us02web.zoom.us/webinar/register/WN_j104ZuE5QjCgJ4xPf9jcxg#/registration","published_at":"2024-11-01T16:08:29Z","author_name":"Luke Malanga","url":"/feed/177172","canonical_url":"https://wefunder.com/feed/177172"},{"id":176927,"entity_id":"wefunder:feed_item:176927","type":"FeedItem::Update","visibility":"public","title":"We’re a Semifinalist in the 2024 Arizona Innovation Challenge!","preview":"We’re excited to share that\u0026nbsp;DataBiologics\u0026nbsp;has been selected as one of the 25 semifinalists for the 2024 Arizona Innovation Challenge (AIC)! Out of 130 applicants, we’re honored to be recognized by the\u0026nbsp;Arizona Commerce Authority\u0026nbsp;as a top contender for driving next-gen innovation.This competition is more than just a milestone—it’s an incredible opportunity to connect with other innovative startups, refine our business, and bring more visibility to the impact we’re making in ...","published_at":"2024-10-23T15:27:09Z","author_name":"Luke Malanga","url":"/feed/176927","canonical_url":"https://wefunder.com/feed/176927"}],"q_and_a":[{"id":293289,"entity_id":"wefunder:comment:293289","question":"Congratulations on the great progress lately! I'm impressed and interested and have a few questions I'd like to ask- 1. I see the company has been around since 2017. Could you explain why progress was slow over the past 6-7 years, and what actions have been taken to drive the growth projections shown in the pitch deck? 2. You mention operational expenses averaging $63,670/month and a burn rate of $24,024/month, with an intent to be profitable in 6 months. Could you provide more details on how you plan to achieve this? Also, if the Wefunder raise doesn't meet expectations, how do you plan to reach cash flow positive while continuing to grow? 3. In researching the competitive landscape, I’d like to know who your direct competitors are and how you differentiate from them. 4. Regarding valuation, how was the $10M valuation determined in this current startup funding winter? 5. In terms of voting power, do the founders not own any equity? Holder Securities Held Power Leah Braddell 7,800,000 Common Stock 33.3% Luke Malanga 7,800,000 Common Stock 33.3% 6. Are you not VC-backed? If not, could you explain why? 7. Also, do you have any mobile-friendly apps?","author_name":"Badal Haider","votes":3,"created_at":"2024-09-30T02:46:17Z","canonical_url":"https://wefunder.com/databiologics#question-293289","answers":[{"id":294597,"entity_id":"wefunder:comment:294597","answer":"Q: Regarding valuation, how was the $10M valuation determined in this current startup funding winter? A: Our prior round of $645k was raised on a $6M pre-money SAFE. This valuation and SAFE offering were in place before I joined the company and when the company was generating minimal early revenue. The founders had made significant investments in technology development, and the company had an early database just beginning to capture long-term outcomes. Our rationale for raising our valuation just slightly to $9-10M post-money in this round is based on the significant traction and revenue growth we’ve seen over the last 12 months, surpassing $500k ARR in Q2, a key milestone in the SaaS industry that aligns to SAFE offerings we see from comparable companies. Additionally, both our product capabilities and database size now have significant acquisition value compared to a few years ago. We believe we are priced competitively for this round, which will accelerate us to the next revenue milestone, so that we can pursue a Series A priced round at a much high valuation, giving our early SAFE holders a near-term conversion opportunity. Q: In terms of voting power, do the founders not own any equity? A: We converted to a C corporation in 2023 and have structured our cap table to maximize incentives for our executives, employees, advisors, and future investors. DataBiologics has 52M authorized common shares, 33.8M of which are fully diluted across the original 3 founders, CEO, COO, and employee equity pool. The three original founders each have 2.6M shares, representing 7.692% fully diluted ownership. Luke (COO) and I (CEO) each have 7.8M, or 23.007% fully diluted ownership each. Our equity incentive pool has 10.4M shares, or 30.769% fully diluted ownership. The founders and executives are fully-vested, common stock holders with voting rights through both ownership and current roles on the board today. We have a 5-member board, with each of the 3 founders holding a voting seat along with seats for the CEO and COO. I am President and Chairman of the Board. Dr. Chris Rogers serves as both Chief Medical Officer is Secretary of the board. Dr. Jay Bowen is Treasurer of the Board and Chief Scientific Officer. Luke represents his seat as well as the seat for father’s estate. Our physician founders remain actively involved, committed, and incentivized long-term with the company. As practicing physicians, they have prioritized incentivizing the management team and employees through equity to maximize the company's potential for growth and future talent acquisition. Q: Are you not VC-backed? If not, could you explain why? A: Yes we are VC backed through Expert Dojo and Launch Factory, both are accelerator funds based in Southern California focused on early-stage companies. We are focusing on building relationships with VC funds for our next stage of fundraising. We’re actively talking with Series A stage investors who will align best with our exit strategy. Q: Also, do you have any mobile-friendly apps? A: Our application is browser-based, so mobile friendly, and there is no need to download or install software for providers or patients. This is an important feature for our business in healthcare today, as the need to download, update, and install applications is a deterrent for engagement.","author_name":"Leah Braddell","votes":4,"created_at":"2024-10-21T22:26:44Z"},{"id":294595,"entity_id":"wefunder:comment:294595","answer":"Hi Badal! Thanks for your thoughtful questions and time last week! I'll take each question one at a time. Q: I see the company has been around since 2017. Could you explain why progress was slow over the past 6-7 years, and what actions have been taken to drive the growth projections shown in the pitch deck? A: The company was originally formed to serve a small group of physician founders and their immediate network, not necessarily with a vision to form a high growth tech company. Our founding physicians needed a solution to track clinical outcomes in their own private practices as they adopted new and experimental treatments without the financial and operational support typical of academic programs. Initially, the focus was limited to meeting their own needs for gathering and analyzing real-world evidence. However, as the regenerative medicine field grew rapidly, both in product options on the market and other physicians seeking to train on the techniques our founders have deployed for decades, it became clear that the opportunity extended far beyond their own practices. Recognizing the broader potential, the founders set out to find a unique CEO with a vision to scale the company and expand its impact. This strategic shift positioned the company to capitalize on the growing market, leading to accelerated growth and the ambitious projections seen today. With my background in both research and the commercialization of medical technology, I was able to quickly assemble early product-market fit with a monetizable database and subscription offering that aligned with the needs of both healthcare providers and industry stakeholders. By leveraging my deep experience, we transitioned from a small, niche solution to a scalable platform that not only supports clinicians in tracking outcomes, but also serves the broader medical and biotech industries with valuable, real-world evidence. This shift has fueled our rapid growth and positioned us to capture a much larger market opportunity.","author_name":"Leah Braddell","votes":3,"created_at":"2024-10-21T22:17:27Z"},{"id":294596,"entity_id":"wefunder:comment:294596","answer":"Q: You mention operational expenses averaging $63,670/month and a burn rate of $24,024/month, with an intent to be profitable in 6 months. Could you provide more details on how you plan to achieve this? Also, if the Wefunder raise doesn't meet expectations, how do you plan to reach cash flow positive while continuing to grow? A: We are confident in achieving profitability within six months through a combination of strategies. Our operational expenses include necessary investments in product development, infrastructure, and scaling our sales and support team, which have positioned us for rapid growth. Now, with these foundational elements in place, we are focusing on driving revenue through our subscription-based model and expanding our customer base. A key factor in our profitability plan is the recurring business we’ve secured in 2024 through multi-year contracts, which will begin contributing to our revenue in early next year. These contracts provide a stable revenue base, reducing financial uncertainty and allowing us to scale with more predictability. In addition to this, we are now ramping up our outbound marketing efforts to both reduce acquisition cost and accelerate new customer pipeline, particularly targeting high-value providers and medical device companies. With our year-over-year ARR growth over 600% and a strong pipeline of recurring revenue, we are confident that the combination of renewal income, optimized systems, and increased subscription sales will enable us to significantly reduce our burn rate and reach profitability within the next six months. The WeFunder raise will help us pull forward developments and more rapidly accelerate growth so that we can pursue a larger capital round sooner, however, if it doesn’t meet expectations, we still have a path to profitability through slower growth, given our strong foundation in recurring revenue and investments already made into operational efficiencies that reduce our burn rate. Q: In researching the competitive landscape, I’d like to know who your direct competitors are and how you differentiate from them? A: There are many solutions on the market for collecting patient-reported outcomes, especially given many health insurance companies, including Medicare, have some requirements for reporting on patient experience for providers to receive reimbursement for care. Although there are numerous solutions for electronic data collection, most are designed to be used by the administrative, academic, and IT layers in healthcare. The end-goal of these solutions is typically routing orders, reporting to submit for billing/compliance purposes or for a narrowly-framed academic study. Studies typically have an end goal of publication or regulatory submission, not broad on-going insights accessible to every-day clinicians We are focused primarily on clinicians who do not have the administrative, IT, or academic infrastructure and funding at their disposal. Even if they do, the type of practice we serve today is primarily offering treatments that don’t follow the typical billing/coding and referral system in healthcare, so there is no repository of data available to meet their interests. Therefore, a uniquely tailored solution was needed to bring together insights clinicians in regenerative medicine care most about right now like what products and treatments are working best and for which patients? It needed to be made possible without requiring time, staff, or money for customization and integration. As a result, our customers have adopted our standardized platform out-of-the-box, requiring less than an hour to implement within their practice. This approach has generated a proprietary, highly-standardized, long-term database in an emerging field where this data does not exist anywhere else. This is our key competitive advantage, as the solutions we produce from this registry are what our customers care about most. Some key competitors in the genre of patient reported outcomes are OBERD, PatientIQ, RedCap, and Code Technology, but there are many more. Both the big players in EHR systems, Epic and Cerner, have ability to add patient outcome surveys. The problem with all of these is specialized resources, money, and on-going maintenance are needed from customers to design, implement, and analyze data. None of these offer a turn-key solution in regenerative medicine and it would be a significant shift in focus and resources for them to do so. We also have an advantage in the network that we’ve curated, the size of our database, and our ability to monetize that database through advanced analytics solutions, something no competitor has. In medicine, clinicians sell clinicians on new technology, whether that’s products or software. Our company being invested in, founded and advised by all of the key educators and influencers in the field today has led to our significant growth and loyalty. That said, while our data collection features are the most efficient, cost-effective way for providers to capture data, we intend to enable streams of data from all other sources in healthcare too, including many of these competitors. Our primary objective is leveraging our unique expertise to ensure providers and patients gain the most value from the data possible, no matter how they acquire the data.","author_name":"Leah Braddell","votes":3,"created_at":"2024-10-21T22:20:44Z"}]},{"id":295687,"entity_id":"wefunder:comment:295687","question":"Can you share your thoughts on how often you will update us on how things are progressing with your goals and business plan? Secondly, do you intend to file the annual report with the SEC? Thanks for your feedback.","author_name":"Karolina Ramirez","votes":1,"created_at":"2024-11-04T16:09:09Z","canonical_url":"https://wefunder.com/databiologics#question-295687","answers":[{"id":295702,"entity_id":"wefunder:comment:295702","answer":"Hi Karolina! Absolutely. Of course, we will comply with the required annual report filing, but more generally we intend to provide quarterly updates on our progress towards goals.","author_name":"Leah Braddell","votes":1,"created_at":"2024-11-04T18:27:30Z"}]},{"id":313106,"entity_id":"wefunder:comment:313106","question":"How do I invest in? Email: gatua.martin.k@gmail.com","author_name":"Martin G","votes":0,"created_at":"2025-08-14T06:39:08Z","canonical_url":"https://wefunder.com/databiologics#question-313106","answers":[]},{"id":299904,"entity_id":"wefunder:comment:299904","question":"I am Canadian, is it possible for me to participate in this opportunity?","author_name":"C. Lagace","votes":0,"created_at":"2025-01-12T05:13:49Z","canonical_url":"https://wefunder.com/databiologics#question-299904","answers":[{"id":299914,"entity_id":"wefunder:comment:299914","answer":"Yes you can! We are able to track data in Canada and have several large clinics using our platform today. Are you a provider interested in the perks with our campaign or a general investor?","author_name":"Leah Braddell","votes":0,"created_at":"2025-01-12T17:36:58Z"}]},{"id":298884,"entity_id":"wefunder:comment:298884","question":"Hi Leah, Your initiative seems very relevant for our times and has a potential. I am an Angel investor, I just made a small investment. I would like to get on a call for a deeper dive. Let us connect.","author_name":"Prakash Sripathy","votes":0,"created_at":"2024-12-25T22:25:50Z","canonical_url":"https://wefunder.com/databiologics#question-298884","answers":[{"id":299012,"entity_id":"wefunder:comment:299012","answer":"Hi Prakash happy to connect. Please reach out to me at leah@databiologics.com and we can find some time in the new year!","author_name":"Leah Braddell","votes":0,"created_at":"2024-12-26T23:07:37Z"}]},{"id":296566,"entity_id":"wefunder:comment:296566","question":"Hello, I hope this message finds you well. I'm Julius, and I came across your fundraising project on WEFUNDER. I'd like to offer my support to help you reach your fundraising goal. I believe my support can make a significant impact on your fundraising project. Please contact me at jsam41199@gmail.com if you would like to discuss this further","author_name":"Samsom Julius","votes":0,"created_at":"2024-11-20T11:44:50Z","canonical_url":"https://wefunder.com/databiologics#question-296566","answers":[]},{"id":296507,"entity_id":"wefunder:comment:296507","question":"Hi there, looks like an interesting project. Can you provide some more detail on the current revenue base? How many customers make up the current base of c.$45k monthly revenues? How are these split across the different pricing packages stated on your website? Are these customers signed up to the subscription model? What is the term of these subscriptions? Do you have any customer churn analysis that you could share (net or gross retention etc.)? Separately, have you done any analysis on the customer lifetime value or customer acquisition costs? Thanks,","author_name":"Hamish Scott","votes":0,"created_at":"2024-11-19T15:50:54Z","canonical_url":"https://wefunder.com/databiologics#question-296507","answers":[{"id":299013,"entity_id":"wefunder:comment:299013","answer":"Hi Hamish thanks for your question! We have a 92% retention rate and several hundred customers ranging from single provider clinic to large academic programs on the provider side. We also serve industry clients like medical device companies, who are seeking sales and marketing insights from our existing database or seeking to prospectively collect data on their products for regulatory and market access requirements. About 45% of our revenue is coming from industry clients and I expect this to transition to an even larger share of revenue in the future now that our database has grown to tracking over 130 products on our platform today. We offer an extremely efficient solution for medical device and pharmaceutical companies seeking to build customer success stories and leverage real-world evidence in medical education. We also just received independent IRB approval for retrospective, patient anonymized research, so engagement from major academic programs and industry alike is growing quickly as we offer a fast path to publication on evidence not available anywhere else!","author_name":"Leah Braddell","votes":0,"created_at":"2024-12-26T23:17:31Z"}]}],"faq":[{"question":"Congratulations on the great progress lately! I'm impressed and interested and have a few questions I'd like to ask- 1. I see the company has been around since 2017. Could you explain why progress was slow over the past 6-7 years, and what actions have been taken to drive the ...","answer":"Q: Regarding valuation, how was the $10M valuation determined in this current startup funding winter? A: Our prior round of $645k was raised on a $6M pre-money SAFE. This valuation and SAFE offering were in place before I joined the company and when the company was generating minimal early revenue. The founders had made significant investments in technology development, and the company had an early database just beginning to capture long-term outcomes. Our rationale for raising our valuation ..."},{"question":"Can you share your thoughts on how often you will update us on how things are progressing with your goals and business plan? Secondly, do you intend to file the annual report with the SEC? Thanks for your feedback.","answer":"Hi Karolina! Absolutely. Of course, we will comply with the required annual report filing, but more generally we intend to provide quarterly updates on our progress towards goals."},{"question":"Hi there, looks like an interesting project. Can you provide some more detail on the current revenue base? How many customers make up the current base of c.$45k monthly revenues? How are these split across the different pricing packages stated on your website? Are these custom...","answer":"Hi Hamish thanks for your question! We have a 92% retention rate and several hundred customers ranging from single provider clinic to large academic programs on the provider side. We also serve industry clients like medical device companies, who are seeking sales and marketing insights from our existing database or seeking to prospectively collect data on their products for regulatory and market access requirements. About 45% of our revenue is coming from industry clients and I expect this to..."},{"question":"Hi Leah, Your initiative seems very relevant for our times and has a potential. I am an Angel investor, I just made a small investment. I would like to get on a call for a deeper dive. Let us connect.","answer":"Hi Prakash happy to connect. Please reach out to me at leah@databiologics.com and we can find some time in the new year!"},{"question":"I am Canadian, is it possible for me to participate in this opportunity?","answer":"Yes you can! We are able to track data in Canada and have several large clinics using our platform today. Are you a provider interested in the perks with our campaign or a general investor?"}]}}}